title: [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
abstract: BACKGROUND
  Neuroendocrine tumors (NETs) present all along the length of the gastrointestinal (GI) tract, from the esophagus to the anus, and they also present in the pancreas.
  
  
  OBJECTIVE
  To classify NETs according to the WHO 2010 criteria and to evaluate their anatomic distribution and clinicopathologic characteristics.
  
  
  METHODS
  A search was carried out in the hospital pathology archives of all the cases diagnosed with carcinoid tumor and neuroendocrine carcinoma of the GI tract and pancreas studied over a period of 11 years (1999-2010). The cases were reclassified according to the WHO 2010 criteria. The clinical case records of each patient were reviewed.
  
  
  RESULTS
  The study group was made up of 127 cases (68 men; 59 women). Age ranged from 24 to 85 years with a median of 52 years. A total of 113 (89.00%) tumors occurred in the GI tract and 14 (11.00%) in the pancreas. Tumor size varied from 0.4cm to 9cm (median: 2.5cm). GI tumor histologic grades were: 54.00% grade 1; 31.00% grade 2; and 15.00% grade 3. Pancreatic tumor histologic grades were: 43.00% grade 1; 36.00% grade 2; and 21.00% grade 3. Ki-67 overexpression was correlated with tumor grade (22.00% grade 3 vs 2.50% grade 1).
  
  
  CONCLUSIONS
  Histologic grade of the gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is one of the most important prognostic factors. The term carcinoid should be eliminated because it does not reflect the biological behavior of these tumors.
authors.affiliation: Departamento de Patología, Hospital de Oncología Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., México. isa.onco@gmail.com
authors.forename: I
authors.initials: I
authors.lastname: Alvarado-Cabrero
authors.forename: J
authors.initials: J
authors.lastname: de Anda-González
authors.forename: B
authors.initials: B
authors.lastname: Hernández-Hernández
authors.forename: A
authors.initials: A
authors.lastname: Mantilla-Morales
authors.forename: R
authors.initials: R
authors.lastname: Valencia-Cedillo
authors.forename: R
authors.initials: R
authors.lastname: Medrano-Guzmán
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006761:Hospitals; D006801:Humans; D007414:Intestinal Neoplasms / Q000150:complications / Q000473:pathology* / Q000628:therapy; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008495:Medical Oncology; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000150:complications / Q000473:pathology* / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000150:complications / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D013274:Stomach Neoplasms / Q000150:complications / Q000473:pathology* / Q000628:therapy; D009626:Terminology as Topic; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen